Form 4: Akero Therapeutics CDO Exercises Stock Options

Akero Therapeutics' Chief Development Officer, Catriona Yale, exercised stock options to acquire 8,266 shares of common stock.

Summary

• Catriona Yale, Chief Development Officer of Akero Therapeutics, Inc. (AKRO), exercised stock options on November 4, 2025.
• She acquired a total of 8,266 shares of common stock through two separate option exercises: 3,527 shares at $28.35 per share and 4,739 shares at $21.10 per share.
• Following these transactions, her direct beneficial ownership of common stock is 74,800 shares.
• The reported amount of 70,061 shares was adjusted to correct a previous overstatement in her common stock ownership.
• The exercised options were vested and currently exercisable.

Sentiment

Score: 6

Explanation: The exercise of stock options by a Chief Development Officer can be seen as a moderately positive signal, indicating continued commitment and potential confidence in the company's value, though it's primarily a compensation event.

Positives

• An insider, the Chief Development Officer, exercising options to acquire shares can be interpreted as a positive signal of confidence in the company's future prospects.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

Routine insider transactions like option exercises are common across all industries and typically reflect individual compensation plans rather than broader industry trends. The specific details of the transaction are company-specific.

Comparison to Industry Standards

• NA. This filing reports an individual insider transaction and does not provide data suitable for comparison to global benchmarks or specific comparable companies/projects.

Stakeholder Impact

• Shareholders: The exercise of options increases the number of outstanding shares, though the impact on dilution from a single insider transaction of this size is typically minimal. It may also be viewed as a positive signal of insider confidence.

Key Dates

Keywords

Akero Therapeutics, AKRO, Insider Transaction, Stock Options, Catriona Yale, Chief Development Officer, SEC Form 4, Equity Acquisition